Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dectrekumab
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Intralesional
01
Overview
Dectrekumab is a fully human monoclonal antibody developed by Novartis that specifically targets interleukin-13 (IL-13), a cytokine involved in the pathogenesis of various allergic and inflammatory diseases. By binding to IL-13 with high affinity, dectrekumab neutralizes its activity, thereby inhibiting downstream signaling pathways associated with TH2-driven immune responses. This mechanism is relevant in conditions such as asthma, eosinophilic esophagitis, idiopathic pulmonary fibrosis, keloids, Crohn's disease, and seasonal allergic rhinitis. Dectrekumab reached Phase 2 clinical trials for several indications but development has been discontinued for all known indications[1][3][6][8].
- Other names
- QAX-576QAX576QAX 576
02
Targets
IL-13 (Interleukin-13)
Beyond the preview
Go deeper on dectrekumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dectrekumab.